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Abstract
Background: The ‘My Experience of Taking Medicines’ (MYMEDS) questionnaire is a self-reporting tool for
identifying modifiable adherence barriers among individuals prescribed post-myocardial infarction (MI) secondary
prevention medicines (SPM) in clinical practice. It was found to be a useful tool to support the conduction of
patient-centred consultation in cardiology outpatient leading to improved outcomes including better adherence
to SPM and patient satisfaction. This study describes the rationale and development of the MYMEDS tool, its
performance and usefulness in identifying modifiable barriers to adherence in cardiology medical practice including
user feedback of 204 consecutive post-MI patients who completed an evaluation based on MYMEDS.
Methods: Modifiable non-adherence factors were initially identified based on literature review and stakeholder
feedback. A draft MYMEDS questionnaire was piloted in 10 patients and adapted accordingly. The final version
comprises six sections, covering current medicines, understanding and satisfaction with medicines, concerns about
medicines, practical adherence barriers, fitting medicines into daily routine, and adherence to individual SPMs. The
questionnaire was mailed to post-MI patients who then attended an outpatient medicines optimisation clinic.
Results: Mean age was 70.5 years and 67.6% were male. The tool was effective in revealing modifiable adherence
barriers that could be addressed during the consultation. There were high rates of concern that SPMs could be
harmful (33.2%) or overprescribed (43.2%), practical issues with swallowing medicines (8.2%), opening packaging
(7.3%) or accessing repeat prescriptions (5.2%), forgetfulness (19.7%), and concerns about inconvenience (13.5%).
Mean number of barriers per patient was 1.8 ± 1.5. The medications most commonly associated with non-
adherence were statins (21.5%), angiotensin II receptor blockers (21.1%), and antiplatelet agents (18.5%). In total,
42.5% of patients acknowledged non-adherence behaviour. Patient feedback on MYMEDS was positive, with near-
unanimous agreement that it was simple, clear and not too long, and that it enabled them to raise any concerns
they had about their medicines. Patients reported that their individual medicines related needs were better
addressed.
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Conclusions: MYMEDS is a practical tool that can successfully identify modifiable barriers to SPM adherence which
can be addressed in a clinical setting. It can be easily rolled out in daily clinical practice to enable individualised
person-centred medicines optimisation consultation.
Keywords: Cardiovascular diseases, Medicines adherence, Shared decision making, Myocardial infarction, Secondary
prevention
Background
Adherence issues are a major concern in cardiovascular
(CV) medicine. Indeed, rates of non-adherence to sec-
ondary prevention medicines (SPMs) – such as antihy-
pertensives, statins and antiplatelet agents – have been
estimated at around 40% based on refill data, self-reports
and direct measures [1, 2].
The effects on patient outcomes can be highly signifi-
cant. In a meta-analysis of 44 prospective studies, the
risk of all-cause mortality was reduced by 45 and 29% in
patients with good adherence to statins and antihyper-
tensive agents, respectively, compared to those with poor
adherence [2]. In the post-myocardial infarction (MI)
setting, adherence to SPMs has been shown to signifi-
cantly decrease the risk of further major vascular events
or revascularisation [3].
The underlying causes of non-adherence need to be dis-
entangled and independently understood, if they are then
to be addressed. However, these causes are often complex
and multifactorial, and typically cannot be explained by
fixed factors like sociodemographic status, personality
traits, or disease type and severity [4]. Hence, the reasons
for non-adherence should be explored at an individual
level – particularly those that are modifiable and hence
can be addressed in practice – and interventions should
be tailored to the needs of the particular patient.
In many circumstances, the most effective method for
examining adherence may be patient self-reporting. Al-
though memory and social desirability biases can lead to
overestimation of overall adherence, self-reported non-
adherence is largely reliable [4–8]. Self-report tools are
also pragmatic and inexpensive for use in everyday clin-
ical practice [4].
Many such instruments have been developed and are
widely used in various medical conditions; some of these
have been applied in CV medicine. Examples include the
Single Question (SQ) tool [9], the eight-item©Morisky
Medication Adherence Scale (MMAS-8) [10], the
Adherence Estimator™ (AE) [11], the Medication Adher-
ence Report Scale (MARS) [12], and the Beliefs about
Medicines Questionnaire (BMQ) [13].
These tools were designed primarily to ‘detect’ non-
adherence behaviour (e.g. SQ, MMAS-8, MARS), or to
assess the likelihood of being or becoming non-adherent
(e.g. AE, BMQ). Within some of these instruments, there
are questions that can help to identify specific adherence
barriers. For example, MMAS-8 asks about forgetfulness
– a common cause of non-adherence [4] – and the AE
probes the risk of intentional non-adherence by asses-
sing levels of concern about medicines [11]. The BMQ
explores specific or general beliefs about medicines,
which have been found to be associated with non-
adherence behaviour [13–15]. However, none of these
tools was designed to screen for a broad range of actual
and potential modifiable impediments to adherence.
There are at least two currently available self-reporting
tools that can screen for adherence barriers in patients
with CV disease: one evaluated adherence in patients
taking at least three medicines including enalapril or
captropril, and the second focused on patients with
hypertension [16, 17], but these have important limita-
tions with regard to structure, the setting in which they
were used and their length. We are not aware of any
tools that screen for modifiable barriers to adherence in
a post MI setting.
We therefore designed a self-reporting tool for identi-
fying modifiable barriers to adherence among patients
prescribed CV SPM in normal clinical practice. This
instrument, known as the My Experience of Taking
Medicines (MYMEDS) questionnaire, was derived from
a wide-range literature review, expert input, and an ex-
tensive analysis of adherence behaviour among over 500
patients with coronary artery disease [18–20]. The tool
was used in clinical practice as part of an innovative post
MI medicines and risk optimisation programme which
was highly praised by our patients [21]. With the help of
MYMEDS we were able to address individual patient is-
sues round SPM, reduce patient concerns about their
medications, and ultimately lowering rates of non-
adherence by up to 70% at 3–6months post-clinic [21].
Here, we describe the process of developing MYMEDS,
the structure of the finalised tool, and the adherence data
and patient feedback from 204 consecutive post-MI sub-
jects who completed an evaluation based on MYMEDS.
Methods
Development of the MYMEDS questionnaire
In designing MYMEDS, key principles for the develop-
ment of adherence scales were followed, including con-
sideration of the administration length of the tool,
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reliability and validity, ability to detect adherence bar-
riers, the type of non-adherence detected (intentional vs
unintentional), transferability, generalisability, ability to
assess beliefs about medicines, and the usefulness of the
information it provides to support patients and optimise
their medicines in the context in which it is validated
(coronary artery disease) [22, 23].
Potentially modifiable factors often associated with
non-adherence to SPM were initially identified based on
a literature review. This was followed by an analysis of
our own patients, and these data have been published
elsewhere [18–20]. Among many barriers to adherence
with SPM identified, the most common were forgetful-
ness, worry that medicines could do more harm than
good, feeling inconvenienced about medicines taking,
and not being convinced of the benefit of medicines.
Practical barriers were also significantly associated with
non-adherence.
Following on from this work, representatives of key
stakeholder groups were consulted – including two car-
diologists, three cardiac pharmacists, and two cardiac
nurses – and a draft adherence assessment questionnaire
was then developed. The key focus was to make the tool
as comprehensive as possible while also keeping it con-
cise and practical. The draft questionnaire included do-
mains on the way patients took their medicines and the
regimens adopted, knowledge about individual SPMs,
overall satisfaction and understanding of SPMs, concerns
about SPMs, practicalities when taking SPMs, and self-
reported adherence to individual SPMs. This draft ver-
sion was user tested with a pilot group of 10 patients
from our Cardiology Patient and Public Involvement
Group. After completing the tool, we held a pilot group
discussion focusing on the overall structure of the ques-
tionnaire, any missing dimensions, if any, and the tool’s
usability – in particular, aspects of consistency of under-
standing of questions, readability, length, and repetitive-
ness. Based on their feedback, the questionnaire was
adjusted and then given back to the pilot group for any
final comments before it was finalised for use.
The tool was named ‘My Experience of Taking Medi-
cines’ (MYMEDS) to reassure patients that they could
volunteer information about their medicines-taking be-
haviour without being judged.
Structure and use of the MYMEDS questionnaire
As recommended by the UK National Institute for
Health and Care Excellence [22], the MYMEDS ques-
tionnaire opens with a brief statement designed to make
the patient feel comfortable sharing their experiences:
“Taking medicines is an experience that differs from one
patient to another. In order for us to support you and
provide the help you need, we would like to know how
you are managing with your medicines, what questions
you have, and any concerns that you need addressing.”
The questionnaire itself is composed of six simple-to-
complete sections (Table 1). In section 1, patients pro-
vide essential contextual information: the medicines that
they are taking, when they are administered each day,
and their understanding of why they are taking them.
This would enable clinicians to understand what and
how a patient takes their medicines compared to what is
documented in clinical records, and uncover any
Table 1 Summary of the MYMEDS questionnaire
Section Area of focus Content Completion method
1 Current medicines Medicines being taken, administration times, why the
patient takes them
List of medicines; tick when they take them; state why
they take them
2 Understanding and
satisfaction with
medicines
Understanding of why medicines were prescribed, whether
the patient is convinced of the importance of these
medicines, whether they feel that their medicines are
working
Four-point Likert scale (strongly agree, agree, disagree,
strongly disagree); free text for comments
3 Concerns about
medicines
Level of worry that medicines will cause more harm than
good, concern about being on too many medicines, and
whether medicines need to be altered because of actual or
perceived harm
Four-point Likert scale (strongly agree, agree, disagree,
strongly disagree); free text for comments
4 Practical barriers to
adherence
Problems with opening medicine packaging or reading
labels, swallowing problems, and issues with obtaining
repeat prescriptions
Four-point Likert scale (strongly agree, agree, disagree,
strongly disagree); free text for comments
5 Fitting medicines
into daily routine
Issues with forgetfulness and inconvenience due to taking
medicines
Four-point Likert scale (strongly agree, agree, disagree,
strongly disagree); free text for comments
6 Adherence to
individual SPMs
Adherence levels with each separate SPM being taken Five-point Likert scale for how often each medicine was
taken as prescribed in the past month (all of the time;
nearly all of the time; most of the time; about half the
time; less than half the time)
Final Other Any other issues that the patient wishes to raise Free text
MYMEDS My Experience of Taking Medicines, SPM Secondary prevention medicine
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medicines changes since discharge. This supports better
optimisation of medicines as discussed in the Post MI
Medicines Optimisation Clinic model [21].
Subsequent sections were largely based on Likert
scales. The use of such scales rather than binary yes/no
responses is generally recommended because it improves
the quality of information obtained [22, 24]. For ex-
ample, the frequency of non-adherence behaviours can
be assessed rather than just the presence of non-
adherence [24].
Section 2 explores overall understanding and satisfac-
tion with their medicines. Patients are provided with
four statements about understanding the reasons why
their medicines were prescribed and how well they feel
they are working, and are asked to assess their agree-
ment on a four-point Likert scale (strongly agree, agree,
disagree, strongly disagree).
Sections 3–5 assess specific modifiable barriers to ad-
herence, using the same four-point Likert scale as in sec-
tion 2. A free-text box allows patients to specify which
medicines their concerns involve.
Section 3 explores three areas of anxiety about medi-
cines (e.g. worry that they will cause more harm than
good, or that there are too many of them), section 4 ex-
amines four separate practical concerns associated with
medicines taking (e.g. swallowing problems and prob-
lems getting repeat prescriptions), and section 5 assesses
three issues in fitting medicines into patients’ daily rou-
tine (e.g. relating to forgetfulness or inconvenience).
These issues have been associated with non-adherence
in our research and that of others [4, 20, 22, 25], and
can potentially be addressed in clinical practice.
Section 6 asks about adherence to each individual SPM
over the past month. It is based on a modified version of
the SQ tool [9]. In our experience, this tool alone is not
sufficiently sensitive to distinguish all non-adherence be-
haviour but, within the context of the whole MYMEDS
questionnaire, it can be helpful in identifying specific
problematic medicines [20]. A five-point Likert scale is
used in this section of MYMEDS, and patients are consid-
ered to be non-adherent if they select any answer other
than ‘all of the time’ for adherence to any SPM.
At the end of the questionnaire, patients can write
down in free text any other concerns or issues that they
wish to raise. We have found that when patients are
given an opportunity to be heard, they are often keen to
share more information about their medicines-taking ex-
perience [26].
The study was conducted as part of a new develop-
ment project to improve post MI medicines and risk op-
timisation at our teaching hospital [21]. The present
study includes consecutive patients who completed the
final version of the MYMEDS questionnaire. All had
been identified on the cardiology wards after being
admitted to hospital with MI, and were then scheduled
to attend an outpatient Post MI medicines optimisation
clinic designed to optimise secondary prevention medi-
cines, risk factors and address adherence barriers [21].
The questionnaire was mailed out around 4–6 weeks be-
fore the clinic appointment and patients were asked to
bring it with them for discussion during the consult-
ation. Demographic data were collected as part of that
consultation.
Although the primary purpose of MYMEDS is to iden-
tify barriers to adherence, regardless of the patient’s
actual adherence status, some elements of the question-
naire can be used to identify non-adherence behaviour:
section 2d, ‘at least occasionally, I need to alter my med-
icines on my own to make them work or meet my ex-
pectations’; section 3c, ‘I sometimes alter my medicines
by cutting back or stopping taking them’; section 4c, ‘I
have difficulties or problems getting my repeat prescrip-
tions and would like help ordering them from my GP or
pharmacy’; section 5a, ‘I sometimes forget to take my
heart medicines’; section 5b, ‘I am finding it difficult to
fit one or more of my heart medicines into my daily rou-
tine’; and section 5c, ‘I feel inconvenienced/bothered
about sticking to all my heart medicines’. Acknowledge-
ment of non-adherence behaviour according to at least
one of these six questions was used to generate an
estimate of overall rates of non-adherence. This was not
validated at this stage as it is not the main objective of
MYMEDS.
As the creation of MYMEDS was part of a service
development programme in clinical practice, ethics ap-
proval was not required as advised by our Research and
Innovation department and in line with Health Research
Authority guidance and its decision tools. Data collec-
tion was conducted in accordance with the Declaration
of Helsinki.
Patient feedback on the MYMEDS questionnaire
After attending the clinic, patients were asked to provide
anonymous quantitative feedback about the MYMEDS
questionnaire, based on five questions assessed using a
four-point scale (strongly agree, agree, disagree, strongly
disagree). Qualitative feedback could also be provided
using free text, based on the question ‘What was best
about the service and what can we improve?’. Only an-
swers related to MYMEDS were included in this
analysis.
Results
Effectiveness of the MYMEDS questionnaire in revealing
adherence barriers
The MYMEDS questionnaire was sent to 270 patients
before they attended the medicines optimisation clinic.
In total, 66 individuals did not complete the
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questionnaire, for example because they said they had
not received it in the post or because they preferred to
discuss relevant issues in person.
The performance of the MYMEDS questionnaire
was therefore examined by collating the responses of
204 patients who completed it. The mean age of
these individuals was 70.5 years and most were male
(n = 138; 67.6%) (Table 2). Based on MYMEDS re-
ports, the majority of patients were found to be tak-
ing several different classes of SPM, and most had at
least two regular SPM administration times per day.
There were no significant differences in baseline char-
acteristics between those who completed the ques-
tionnaire (n = 204) and those who did not (n = 66),
other than mean age (70.5 ± 10.9 vs 66.2 ± 14.5 years,
respectively; p = 0.022).
Among those who completed the questionnaire, know-
ledge about individual SPMs was poor: fewer than half
of respondents knew the indications for each of their
SPM medicines.
The tool was effective in revealing many important
modifiable barriers to SPM adherence (Table 3),
which could then be addressed in the medicines opti-
misation clinic. In particular, 33.2% of patients (n =
62/187) were concerned that their SPM would cause
them more harm than good, and 43.2% (n = 82/190)
were concerned about being prescribed too many
medicines; 8.2% (n = 16/194) reported problems with
swallowing medicines, and 7.3% (n = 14/191) said that
they had problems with opening medicine bottles or
packs; 19.7% of patients (n = 38/193) agreed that they
sometimes forget to take one or more of their medi-
cines, and 13.5% (n = 26/193) felt inconvenienced or
bothered about sticking to their SPMs.
Overall, 193 patients (94.6%) completed at least one
question in all four domains of MYMEDS relating to
adherence barriers (sections 2–5). Of these, 33.2% of
respondents (n = 64) had adherence barriers relating
to only one domain, 25.4% (n = 49) had at least one
barrier in two domains, 16.1% (n = 31) in three
domains, and 3.6% (n = 7) in four domains. Across all
domains, 29.0% of respondents (n = 56) had one
adherence barrier, 22.3% (n = 43) had two, 13.5%
(n = 26) had three, 7.8% (n = 15) had four, and 5.7%
(n = 11) had five or more barriers. The mean number
of barriers per patient was 1.8 ± 1.5.
The classes of medication most commonly associ-
ated with non-adherence were statins (n = 39/181;
21.5% of patients), angiotensin II receptor blockers
(ARBs; n = 8/38; 21.1%), and antiplatelet agents (clo-
pidogrel / prasugrel / ticagrelor; n = 32/173; 18.5%)
(Fig. 1). Non-adherence was also described with beta-
blockers (n = 23/169; 13.6%), angiotensin converting
enzyme inhibitors (n = 19/140; 13.6%), and aspirin
(n = 24/176; 13.6%). Among those who reported non-
adherence to individual SPM, 51.3% (n = 23/44) said
that they were non-adherent to only one drug.
Overall, 86 patients (42.2%) used the free text box at
end of the questionnaire to provide a total of 154 add-
itional comments. Key themes are summarised in
Table 4. Almost a third of comments were related to
side effects (e.g. experiencing specific side effects, sus-
pecting particular symptoms were caused by SPMs, or
concern about possible future side effects).
Overall adherence
Acknowledgement of non-adherence behaviour ac-
cording to at least one of six indicator questions in
MYMEDS (sections 2d, 3c, 4c, and 5a–c; Table 3)
was used to generate an estimate of overall rates of
non-adherence. In total, 42.5% of patients (n = 82/
193) who responded fitted these non-adherence
criteria.
Table 2 Patient characteristics
Variable Baseline value
(N = 204)
Age, years, mean (SD) 70.5 (10.9)
Sex, n (%)
Male 138 (67.6)
Female 66 (32.4)
Type of MI, n (%)
NSTEMI 127 (62.3)
STEMI 77 (37.7)
SPM, n (%)
Aspirin 190 (93.1)
Other antiplatelet agent 192 (94.1)
Ticagrelor (twice daily) 159 (77.9)
ACE inhibitor / ARB 188 (92.2)
Twice daily dosing 44 (21.6)
Beta-blocker 180 (88.2)
Twice daily dosing 23 (11.3)
Statin 192 (94.1)
SPM administration times,* n (%)
One regular administration time per day 5 (2.5)
Two regular administration times per day 147 (72.1)
Three regular administration times per day 40 (19.6)
Not completed 12 (5.9)
N = 204. *The total number of times the patient had to take a medicine,
regardless of the number of medicines taken at the point of administration
(i.e. more than one medicine may have been taken at each administration
time). ACE Angiotensin converting enzyme, ARB Angiotensin II receptor
blocker, NSTEMI non-ST-elevation myocardial infarction, MI Myocardial
infarction, SD Standard deviation, SPM Secondary prevention medicine, STEMI
ST-elevation myocardial infarction
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Table 3 Collated results from sections 2–5 of the MYMEDS questionnaire
Statement Response, n (%)
Strongly agree Agree Disagree Strongly
disagree
Section 2: Understanding and satisfaction with medicines
a. I fully understand my heart medicines and why they were prescribed (N = 196) 47 (24.0) 95 (48.5) 44 (22.4) 10 (5.1)
b. My heart medicines seem to be working for me (N = 183) 49 (26.8) 116 (63.4) 15 (8.2) 3 (1.6)
c. I feel convinced of the importance of all my heart medicines (N = 194) 79 (40.7) 102 (52.6) 12 (6.2) 1 (0.5)
d. At least occasionally, I need to alter my medicines on my own to make them
work or meet my expectations (N = 180)
9 (5.0) 17 (9.4) 64 (35.6) 90 (50.0)
Section 3: Concerns about medicines
a. I worry that one or more of my medicines will do me more harm
than good (N = 187)
13 (7.0) 49 (26.2) 87 (46.5) 38 (20.3)
b. I feel concerned about being prescribed too many medicines (N = 190) 15 (7.9) 67 (35.3) 74 (38.9) 34 (17.9)
c. I sometimes alter my medicines by cutting back or stopping taking t
hem (N = 186)
6 (3.2) 9 (4.8) 89 (47.8) 82 (44.1)
Section 4: Practical issues that may be a barrier to adherence
a. I have difficulties or problems opening the medicine bottles or blister
packs and would like a solution or an alternative (N = 191)
2 (1.0) 12 (6.3) 87 (45.5) 90 (47.1)
b. I have difficulties or problems swallowing my medicine(s) and would like a
solution or an alternative (N = 194)
4 (2.1) 12 (6.2) 88 (45.4) 90 (46.4)
c. I have difficulties or problems getting my repeat prescriptions and would like
help ordering them from my GP or pharmacy (N = 192)
3 (1.6) 7 (3.6) 96 (50.0) 86 (44.8)
d. I have difficulties or problems reading the label on the medicines bottle or
box and would like a solution or alternative (N = 191)
2 (1.0) 5 (2.6) 100 (52.4) 84 (44.0)
Section 5: Fitting medicines into daily routine
a. I sometimes forget to take my heart medicines (N = 193) 4 (2.1) 34 (17.6) 78 (40.4) 77 (39.9)
b. I am finding it difficult to fit one or more of my heart medicines into my
daily routine (N = 194)
5 (2.6) 17 (8.8) 89 (45.9) 83 (42.8)
c. I feel inconvenienced/bothered about sticking to all my heart medicines (N = 193) 5 (2.6) 21 (10.9) 90 (46.6) 77 (39.9)
MYMEDS My Experience of Taking Medicines
Fig. 1 Non-adherence to individual SPMs (MYMEDS section 6). Percentages were calculated using the total number of patients who took each
medicine as the denominator (ARB, N = 38; statins, N = 181; beta-blocker, N = 169; ACE inhibitor, N = 140; clopidogrel / prasugrel / ticagrelor, N =
173; aspirin, N = 176). ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blocker; MYMEDS, My Experience of Taking Medicines;
SPM, secondary prevention medicine
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Patient feedback on MYMEDS
A total of 131 patients provided feedback on MYMEDS,
and this showed that the questionnaire was well received
(Table 5). There was near unanimous accord that it
helped them to think about their medicines (n = 127;
96.9% agreed), and that it enabled them to raise any
questions or concerns they had about their medicines
during the subsequent consultation (n = 128; 97.7%). In
addition, almost all of the patients who provided feed-
back agreed that the questionnaire was simple and clear
(n = 128; 97.7%), and that the length was acceptable (n =
130; 99.2%).
Furthermore, feedback from individual patients sug-
gested that the MYMEDS questionnaire was straight-
forward to complete (“It was easy to understand, and
easy to answer”), facilitated improved understanding
of individual therapies (“It made me think what I was
taking rather than just accepting the meds given”; “I
found the questionnaire helpful – in that it encour-
aged me to find out and understand more about my
medications”), and aided medicines optimisation
(“The questionnaire helped the consultant easily find
some discrepancies about my medicines and altered
them accordingly”). Some suggestions were also made
for improving the overall service, particularly relating
to transactional aspects such as waiting time and
environment; this feedback has fed into the ongoing
optimisation of the clinic. There were very few nega-
tive or improvement comments about MYMEDS. For
example: one patient commented “.. expect some
elderly patients to require some assistance to
complete”. Indeed, as with other questionnaires, some
elderly patients may need help to complete MYMEDS.
The clinic invitation letter acknowledges that some
patients may need the help of their carers to
complete the questionnaire.
Discussion
This study demonstrated the capacity of the MYMEDS
self-reporting questionnaire to identify actual and poten-
tial barriers to adherence to SPM – that could be ad-
dressed in clinical practice – in 204 consecutive post-MI
patients. Moreover, user feedback was highly positive,
with nearly all patient agreeing that the tool was simple
to use and facilitated discussion of issues and concerns
around medicines taking. Levels of patient engagement
were high, with almost half of respondents using the
free-text section at the end of the questionnaire to share
additional issues and concerns relating to their SPM.
Importantly, the tool was not used in isolation. In-
stead, completed questionnaires were carefully reviewed
during a subsequent outpatient medicines optimisation
clinic designed to address the barriers identified [21]. At
our centre, this clinic follows a multidisciplinary format:
patients who need no further non-pharmacological in-
terventions see the consultant cardiology pharmacist
(with the option of a review by a cardiologist if needed),
while patients requiring further interventions such as
Table 4 Key themes raised in the free-text section of the MYMEDS questionnaire
Theme Details
Side effects Mostly relating to experiencing specific side effects, suspecting that they were caused by one or more medicines,
or concern about possible side effects (e.g. headaches, anxiety, cold hands, panic attacks, dizziness, cramps, bruising,
feeling tired, breathlessness)
Pharmaceutical form Issues around different formulations, generics, size of tablets, dissolving tablets, and desire for easier-to-swallow
formulations
Administration Issues around the time of the day to take medicines, taking medicines together, whether ‘twice a day’ mean 12 h apart
Medicines interactions Queries about drug–drug and drug–food/drink interactions, and concerns about taking too many medicines for the same
thing (e.g. too many blood pressure-lowering medicines)
Rationale for medicines Questions on why to take certain medicines when key parameters were within the target range (e.g. why take
hypertension medication when blood pressure is well controlled, why take a statin when blood cholesterol is low)
Service issues In particular, reporting service problems (e.g. with obtaining repeat prescriptions)
Requests for further
information
In particular, more information about side effects, or about the length of time on medicines (e.g. how long time to take a
high-dose statin, when to stop a second antiplatelet, extending dual antiplatelet therapy)
Role of carer Notes on the roles of their carers in taking medicines (e.g. my family support me, my daughter sorts out my medicines)
MYMEDS My Experience of Taking Medicines
Table 5 Patient feedback on the MYMEDS questionnaire
Statement Agree, n (%) Disagree, n (%)
The questionnaire helped me think
about my medicines
127 (96.9) 4 (3.1)
The questionnaire was simple and clear 128 (97.7) 3 (2.3)
The length of the questionnaire was
acceptable
130 (99.2) 1 (0.8)
The questionnaire was helpful in
making me think about issues related
to my medicines before visiting the clinic
130 (99.2) 1 (0.8)
The questionnaire helped me to raise
any concerns I had about my medicines
during the consultation
128 (97.7) 3 (2.3)
MYMEDS My Experience of Taking Medicines. N = 131
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staged percutaneous coronary intervention see a cardi-
ologist (with the option of referral to the consultant
pharmacist if needed). Consultations typically last
around 20 min, but individuals with more complex is-
sues – such as known or elevated risk for poor adher-
ence – can attend an enhanced session that lasts around
45min. All consultations take a patient-centred ap-
proach, using the completed MYMEDS questionnaire as
a basis for optimisation of SPM regimens and discussion
of adherence issues. A full management plan is then
agreed, including key action points for the patient (or
carer) and their healthcare team. This model has been
successful in optimising SPM selection and dosing, de-
creasing patient concerns about their medications, and
ultimately lowering rates of non-adherence by up to 70%
at 3–6 months post-clinic [21]. Readmission rates have
also fallen [21].
In this model, patients have access to both a consult-
ant cardiology pharmacist and a cardiologist, but most
are seen only by the pharmacist. This opens up places at
the cardiology outpatient clinic and improves overall
capacity. Moreover, a recent analysis of data from eight
systematic reviews of adherence solutions found that in-
terventions provided by a multidisciplinary team may be
more successful in improving adherence compared to
those delivered by physicians alone [27].
Use of the MYMEDS questionnaire has played a key
role in making the clinic more patient-centred by
highlighting individual concerns and building confidence
that the consultation will focus on addressing these is-
sues. The overall clinic model has helped to facilitate
shared decision making [21], in alignment with current
guidelines for improving adherence and optimising med-
icines taking [22, 28].
Importantly, the MYMEDS questionnaire focuses on
actual and potential adherence issues that can be modi-
fied in clinical practice. Much of the research into the
causes of non-adherence has assessed fixed factors or
those that cannot be modified in clinical practice, such
as sociodemographic and financial status, gender, age,
and disease type and severity [4, 29]. The impact of these
factors has proved to be inconsistent. By focusing on a
wide range of modifiable factors, with a known impact
on adherence [4, 20, 22, 25], the MYMEDS question-
naire can be used to start a personalised conversation
that puts the patient in control and provides an adapt-
able action plan for overcoming specific barriers.
The issues identified in the current cohort of patients
included high rates of concern that SPMs could be
harmful (33.2%) or overprescribed (43.2%), practical is-
sues with swallowing medicines (8.2%), opening pack-
aging (7.3%) or accessing repeat prescriptions (5.2%),
forgetfulness (19.7%), and concerns about inconvenience
(13.5%). These data are broadly in line with previous
work on the underlying causes of non-adherence to CV
medicines [20, 30, 31]. Furthermore, all of these issues
can potentially be mitigated through straightforward,
targeted interventions, such as patient education, adjust-
ments to the treatment plan, and/or enhanced support
from friends and family. For example, patients with
problems swallowing medicines can be switched to a dif-
ferent formulation or doses can be split, and patients
with concerns about harmful effects can be listened to,
educated and reassured about specific medicines.
The single question approach to assess adherence in
section 6 of the tool was previously validated in various
studies [9, 32]. Our work shows that this form of adher-
ence assessment tends to have low sensitivity and high
specificity compared to MMAS-8 validated tool [20, 21,
32]. However, the modification of the tool was useful in
identifying individual SPM that patients had issues with.
The intention in developing the MYMEDS tool was to
identify barriers to adherence rather than to assess spe-
cifically whether the patient was adherent or not. How-
ever, apart from section 6, some other elements of the
questionnaire do identify non-adherence behaviour.
Based on these, we estimated that around 42.5% of pa-
tients appeared to be non-adherent. This aligns with
previous data on adherence with SPM in this setting [1].
This aspect of the tool needs to be validated in the
future.
Regarding specific SPMs, adherence problems were
most common with statins, ARBs and antiplatelet
agents. Non-adherence was usually selective: many pa-
tients were non-adherent to one medicine while adher-
ing to all of the others. This aligns with our previously
published experience [20]. Once issues were identified at
an individual level, they were often easily resolved, and
we have discussed some of the relevant strategies in pre-
vious publications [20, 21]. For example, some patients
had safety concerns about statins, which could typically
be alleviated through discussion and education and/or
by switching to another statin. Others were non-
adherent to a statin because it was the only medicine
they took at night, and adherence improved once it was
moved to morning administration. Indeed, an important
revelation from MYMEDS was how many patients had
two or even three different medicine administration
times each day, and how often this was associated with
easily solvable adherence issues. For example, some pa-
tients took an evening dose of ticagrelor with dinner and
took a statin separately before going to bed (due to an
instruction to ‘take at night’). Adherence could often be
improved by advising them to take both at the same
time or by offering a once-daily alternative to ticagrelor,
if appropriate.
There are other tools that have been developed to as-
sess the extent of and underlying reasons for non-
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adherence [16, 17]. For example, Svarstad and colleagues
developed the Brief Medication Questionnaire (BrMQ)
based on the Health Collaboration Model [16, 33]. The
BrMQ explores the patient’s medicines regimen, asking
them to list each one and answer specific questions cov-
ering several domains which are similar to MYMEDS.
While this approach may provide comprehensive infor-
mation, it can be time consuming if the patient is taking
many medicines. In the first iteration of MYMEDS,
SPMs were listed separately and respondents were ques-
tioned on each. However, the pilot group of patients dis-
liked this format and considered it too lengthy. Thus, in
the final version, patients were given general questions
and then identified which medicines were problematic.
For example, they were asked about forgetting to take
medicines, and could specify which ones in a free-text
box. MYMEDS also covers some issues that the BrMQ
does not. For example, it actually enables identification
of actual administration times (rather just how many
times a day) and asks about difficulties with swallowing
medicines. In addition, MYMEDS ends with an open
question that allows patients to share their thoughts
and medicines-taking experiences. This was often a
particularly useful instrument for discussion in the
subsequent clinic.
More recently, Voils and co-workers developed a self-
report measure that assesses both the extent of and
reasons for medication non-adherence among patients
with hypertension [17]. This tool is another excellent at-
tempt to understand self-reported reasons behind non-
adherence. The instrument first asks the patient to report
the extent of non-adherence and then focuses on rating
potential underlying reasons for non-adherence. By con-
trast, MYMEDS is deployed to identify actual or potential
barriers irrespective of current adherence levels, and in-
deed the measuring of adherence itself is a secondary goal.
This is a crucial difference because an adherent patient
should also be supported if they are faced with a barrier
which is making their medicines-taking experience more
challenging. In addition, an adherent patient may become
non-adherent in the future if the barrier to adherence is
not resolved. MYMEDS is also less lengthy to complete,
and includes a number of potential barriers not listed in
the Voils tool (e.g. difficulties accessing repeat prescrip-
tions or opening packaging).
Although the MYMEDS questionnaire was specifically
used in post-MI patients in the current study, there is
no theoretical reason why it could not be used with any
other individual taking preventive CV medicines. Indeed,
the near unanimous agreement that MYMEDS was both
valuable and easy to use suggests that it could be use-
fully deployed in many other patients with CV disease –
albeit that section 6 might need to be modified to reflect
appropriate classes of medicines. In addition, while a
paper version was used during the development and
testing of the tool, in the future we will be exploring
electronic versions on various platforms.
We should acknowledge some limitations of the
present study. First, MYMEDS is based on patient self-
reporting, and therefore has potential memory and social
desirability biases that may lead to over-estimation of
adherence. However, there is no reason to believe that
non-adherence behaviours identified via MYMEDS are
inaccurate. Second, MYMEDS was not validated against
another adherence tool or prescription refill data. How-
ever, estimation of overall adherence rate was not the
main purpose of developing the questionnaire. Further-
more, when validating a self-reported tool, the usual
concerns are around lack of sensitivity and under-
estimation of non-adherence, which does not seem the
case with MYMEDS. Nonetheless, formal validation
might be an important future undertaking. Third, the
present assessment of the questionnaire was based on a
single-centre, non-comparative study design. Undoubt-
edly, a prospective, multicentre, randomised controlled
trial of the use of MYMEDS to improve adherence (and
patient outcomes) would be valuable. Finally, there is a
possibility of reporting bias in the patient feedback on
MYMEDS. Because this was completely anonymised, the
characteristics of those who did and did not provide
feedback cannot be compared. However, the response
rate was high, which suggests that a reasonable cross-
section of patients may have responded.
Conclusions
Overall, this study shows that MYMEDS is a simple-to-
use, practical tool that can successfully identify many ac-
tual and potential modifiable barriers to SPM adherence.
It can easily be rolled out in clinical practice to direct
consultations and improve their patient focus.
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